<DOC>
	<DOCNO>NCT02756039</DOCNO>
	<brief_summary>Clinical experience investigation ( CEI ) conduct confirm follow characterise safety efficacy Tagrisso Tablets actual clinical use . 1 . Incidence adverse drug reaction ( ADRs ) actual clinical use 2 . Factors may affect safety efficacy product ( especially analysis incidence risk factor interstitial lung disease ( ILD ) event ) 3 . Information ADRs expect `` Precautions Use '' package insert Japan</brief_summary>
	<brief_title>Tagrisso Tablets Clinical Experience Investigation ( All Case Investigation )</brief_title>
	<detailed_description />
	<mesh_term>Osimertinib</mesh_term>
	<criteria>patient treat product No Account ( NA )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>